Bruce CarlsonBusiness InsightsU.S. IVD market reaches $53 billionAccording to Kalorama Information, the U.S. IVD market is projected to grow at a 2.4% average annual rate through 2027.March 22, 2023Business InsightsIVD physician office market was $8.3 billion in 2022: KaloramaAn increase in the number of diseases for which physician offices are often the first to test is influencing physician office lab IVD revenue growth.January 23, 2023Liquid Biopsy$1.3 billion liquid biopsy market represents the present and future of clinical oncology: KaloramaThe liquid biopsy market can be segmented by the type of analyte detected and analyzed. There are four main categories: circulating tumor DNA (ctDNA), circulating tumor cells (CTCs), exosomes and other analytes, and multiple analytes.January 19, 2023Business InsightsHighly competitive molecular diagnostics market reaches $21B: KaloramaThe market largely consists of COVID-19 sales, but future growth in the market will be fueled by other applications, according to Kalorama Information.November 8, 2022InfectiousInfectious disease world market to reach $4.9B in 2026: KaloramaAlthough COVID-19 and monkeypox dominate the headlines, numerous other known infectious diseases also threaten world populations.October 14, 2022Technology Commercialization$54B U.S. IVD market to grow 2% per year for five years: KaloramaTest makers will need to get creative for growth, and they can do so by focusing on a few growth-rich segments, such as point-of-care products and tissue diagnosticsOctober 11, 2022Technology CommercializationContract manufacturing market for IVD products to reach $16.1B in 2022: KaloramaEvolving trends in IVD contract manufacturing will result in developed economies retaining more than three-fourths of the total global demand.October 4, 2022ConsumerBoosted by COVID-19 and cancer tests, IVD market reaches $127B: KaloramaThat's the finding from Kalorama's market research report, The Worldwide Market for In Vitro Diagnostics, 15th edition.August 25, 2022PCRLaboratories stand ready if needed for monkeypox threatThe monkeypox virus is a relative of the smallpox virus that's weaker in severity and transmission than smallpox and that can be detected with PCR. The first draft genome from a swab of a confirmed case was published last week; this will allow the development of PCR tests for detecting the virus from scabs or blisters of potentially infected people. Testing is already available at the U.S. Centers for Disease Control and Prevention (CDC) and in major world laboratories. At least one IVD vendor has acted promptly with this disease event: on Wednesday, May 25, Roche Diagnostics announced it has launched a monkeypox PCR test.May 25, 2022Business Insights10 reasons for growth in the market for infectious disease testingMay 17, 2022Page 1 of 7Next PageTop StoriesBusiness InsightsOhio, Kentucky doctors convicted in scheme to bill Medicaid for millions of dollars in unnecessary urinalysis testingThe doctors billed Medicaid for millions of dollars in medically unnecessary urinalysis testing for their patients, including testing allegedly conducted on faulty machinery, OIG said.CancerImpact of circadian rhythms on cellular functions points to better ways to treat cancerBusiness InsightsU.S. IVD market reaches $53 billionSequencingRNA-seq analysis links protein to spread of pancreatic cancer, reveals potential drug targetCOVID-19Rapid nirmatrelvir treatment in study reduced long-COVID risk
